Oppenheimer & CO Inc Biomarin Pharmaceutical Inc Transaction History

Oppenheimer & CO Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$83.81 - $99.0 $163,345 - $192,951	1,949 Added 70.49%	4,714 $411,000
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $5,411 - $6,994	71 Added 2.64%	2,765 $266,000
Q3 2023 Nov 07, 2023	SELL	$85.07 - $94.48 $51,212 - $56,876	-602 Reduced 18.26%	2,694 $238,000
Q2 2023 Aug 02, 2023	BUY	$86.68 - $100.3 $31,984 - $37,010	369 Added 12.61%	3,296 $285,000
Q1 2023 May 10, 2023	BUY	$87.74 - $117.27 $256,814 - $343,249	2,927 New	2,927 $284,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.